Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Nanoscale Horiz. 2021 Apr 22;6(5):393–400. doi: 10.1039/d0nh00679c

Figure 1: Schematic of tumor bearing mice being co-administered with latrunculin A-loaded macropinocytosis inhibitory nanoparticles (MiNP).

Figure 1:

MiNP were developed and evaluated for their effect on the accumulation of a targeted “effector” nanoparticle via subcutaneous and intravenous injection. As MiNP interferes with macropinocytosis but not receptor-mediated endocytosis, pre- and/or co-injection of MiNP with an effector nanoparticle displaying targeting ligands allows enhanced uptake by cells expressing the target receptor. As an example, MiNP are shown enhancing the targeting of receptors highly expressed within tumor microenvironments by interfering with off-target mononuclear phagocyte system (MPS) clearance.